This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
Paclitaxel has been widely used as an anti- mitotic agent in chemotherapy for a variety of cancers and adds substantial efficacy as the first-line chemotherapeutic regimen for ovarian cancers. However, the frequent occurrence of paclitaxel resistance limits its function in long-term management, scientists in the United States report.
We care about your feedback. Let us know how we can improve your CancerCompass experience.